TLR7/8 antagonist 2
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of TLR7/8 with IC50s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases[1].
Product Specifications
CAS Number
[2769085-03-0]
UNSPSC
12352005
Target
Toll-like Receptor (TLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tlr7-8-antagonist-2.html
Purity
99.68
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=CC(C2=C(C=C3C(NN=C3N[C@H]4CCNC[C@@H]4F)=C2)C5CC5)=CC(C)=N1
Molecular Formula
C22H26FN5
Molecular Weight
379.47
References & Citations
[1]Claudia Betschart, et al. Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an In Vivo Efficacious TLR7/8 Antagonist.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human SLC23A1 shRNA (UAS) - Lentiviral human SLC23A1 shRNA (UAS, iRFP) (100)
